AUTHOR=Bouchè Victoria , Aldegheri Giovanni , Donofrio Carmine Antonio , Fioravanti Antonio , Roberts-Thomson Samuel , Fox Stephen B. , Schettini Francesco , Generali Daniele 

TITLE=BRAF Signaling Inhibition in Glioblastoma: Which Clinical Perspectives?

JOURNAL=Frontiers in Oncology

VOLUME=11

YEAR=2021

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.772052

DOI=10.3389/fonc.2021.772052

ISSN=2234-943X

ABSTRACT=<p>IDH-wild type (wt) glioblastoma (GB) accounts for approximately 90% of all GB and has a poor outcome. Surgery and adjuvant therapy with temozolomide and radiotherapy is the main therapeutic approach. Unfortunately, after relapse and progression, which occurs in most cases, there are very limited therapeutic options available. <italic>BRAF</italic> which plays a role in the oncogenesis of several malignant tumors, is also involved in a small proportion of <italic>IDH</italic>-wt GB. Previous successes with anti-B-Raf targeted therapy in tumors with V600E <italic>BRAF</italic> mutation like melanoma, combined with the poor prognosis and paucity of therapeutic options for GB patients is leading to a growing interest in the potential efficacy of this approach. This review is thus focused on dissecting the state of the art and future perspectives on <italic>BRAF</italic> pathway inhibition in <italic>IDH</italic>-wt GB. Overall, clinical efficacy is mostly described within case reports and umbrella trials, with promising but still insufficient results to draw more definitive conclusions. Further studies are needed to better define the molecular and phenotypic features that predict for a favorable response to treatment. In addition, limitations of B-Raf-inhibitors, in monotherapy or in combination with other therapeutic partners, to penetrate the blood-brain barrier and the development of acquired resistance mechanisms responsible for tumor progression need to be addressed.</p>